Vitae Pharmaceuticals, NASDAQ:VTAE, VTAE

Intraday Info: Synergy Pharmaceuticals Inc (NASDAQ:SGYP) locked on 29/12/2016 at $5.92. It has average volume 5.06 million whilst it totals volume 3.60M. The company has EPS -1.23 and according to analysts next quarter EPS and next year estimate EPS will -0.20 and -0.46 respectively. And it total income 169.20 million.

Ownership Summary: Synergy Pharmaceuticals Inc has total institutional ownership 55.96% while its total outstanding shares 180 millions that’s value of holdings $596 million.

Active Positions: In the latest year, SGYP 85 holders have raised its positions while it contains total 10,818,256 shares. And the strength of reduced positions holders and held positions holders are 47 and 34 respectively.

New and Sold Out Positions: In SGYP force of new positions holders 32 and it has total shares 5,751,791. And force of sold out positions holders 15 and it has 2,749,672 shares.

Comparison with Other Company: The Market Value of SGYP is $1M below from AbbVie Inc. market value which is $101M. Current Last Sale of SGYP is $5.92 below from ABBV current last sale which is $62.73.

Synergy prescribed drugs Inc. declared superb top-line effects from the second one of two pivotal segment three scientific trials evaluating the efficacy and safety of plecanatide, an investigational as soon as-each day orally-administered compound, in 1,054 person patients with irritable bowel syndrome with constipation (IBS-C).

Preliminary evaluation of the data indicates that both plecanatide three mg and six mg doses met the have a look at’s number one endpoint and confirmed statistical significance in the percentage of patients who were typical Responders assessment to placebo at some point of the 12-week remedy length (30.2% in three mg and 29.5% in 6 mg dose companies contrast to 17.8% in placebo; p<0.001 for three mg and p<zero.001 for 6 mg).

The most not unusual negative occasion become diarrhea which happened in 5.4% of sufferers in 3 mg and 4.three% of patients in 6 mg dose agencies comparison to 0.6% of placebo-treated patients.



Please enter your comment!
Please enter your name here